PALO ALTO, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the publication of new analyses in Circulation: Heart Failure, examining kidney function in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis. This publication was based on post-hoc analyses of data from randomized, double blind, placebo-controlled trials including the Phase 2 study and the Phase 3 ATTRibute-CM study. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

“In these data, we observed early and sustained cardiorenal benefits of acoramidis treatment with a pattern similar to what we see with drugs such as ACE inhibitors, ARBs, and SGLT2 inhibitors, suggesting acoramidis may have a direct effect on kidney function. These effects have not been reported with other ATTR-CM medications. Acoramidis appears to have a protective effect on the heart and the kidney simultaneously, with potentially meaningful implications for long-term survival and reduced cardiovascular hospitalizations. Kidney dysfunction is pervasive in this population and an independent predictor of mortality from ATTR-CM. For a patient population that is older, sicker, and increasingly surviving long enough for organ preservation to matter, these cardiorenal observations represent an important advancement in the care of patients living with ATTR-CM,” said Professor Jeffrey Testani, M.D., M.T.R. of the Yale School of Medicine, U.S., and first author on the Circulation: Heart Failure manuscript.